MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer

Celina García-García, Martín A. Rivas, Yasir H. Ibrahim, María Teresa Calvo, Albert Gris-Oliver, Olga Rodríguez, Judit Grueso, Pilar Antón, Marta Guzmán, Claudia Aura, Paolo Nuciforo, Katti Jessen, Guillem Argilés, Rodrigo Dienstmann, Andrea Bertotti, Livio Trusolino, Judit Matito, Ana Vivancos, Irene Chicote, Héctor G. PalmerJosep Tabernero, Maurizio Scaltriti, José Baselga, Violeta Serra

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Fingerprint Dive into the research topics of 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences